Immunis is changing the course of immune-related diseases and ageing.

Immunis is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human stem cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health.